RENEB – Realising the European Network in Biological Dosimetry


¹ Institut de Radioprotection et de Sûreté Nucléaire (France), ² Health Protection Agency (United Kingdom), ³ Helmholtz Centre Munich (Germany), ⁴ Universitat Autonoma de Barcelona (Spain), ⁵ Bundeswehr Institut für Radiobiologie / Universität Ulm (Germany), ⁶ National Research Institute for Radiobiology & Radiohygiene (Hungary), ⁷ Leiden University Medical Center (The Netherlands), ⁸ Instituto Superior di Sanità (Italy), ⁹ Instituto Tecnológico e Nuclear, Instituto Superior Técnico, Universidade Técnica de Lisboa (Portugal), ¹⁰ National Center for Radiobiology and Radiation Protection (Bulgaria), ¹¹ Stockholm University (Sweden), ¹² Servicio Madrileño de Salud - Hospital General Universitario Gregorio Marañón, ¹³ Norwegian Radiation Protection Authority (Norway), ¹⁴ Radiation and Nuclear Safety Authority (Finland), ¹⁵ Fundacion para la Investigacion del Hospital Universitario la Fe de la Comunidad Valenciana (Spain), ¹⁶ University of Tuscia (Italy), ¹⁷ National Centre for Scientific Research Demokritos (Greece), ¹⁸ Institutul National de Sanatate Publica (Romania), ¹⁹ Commissariat à l’Énergie Atomique (France), ²⁰ Institut Chemii i Techniki Jadrowej (Poland), ²¹ Agenzia Nazionale per le Nuove Tecnologie, L’Energia e lo Sviluppo Economico Sostenibile (Italy), ²² Universiteit Gent (Belgium), ²³ Bundesamt fuer Strahlenschutz (Germany)

philippe.voisin@irsn.fr

ABSTRACT

Creating a sustainable network in biological dosimetry that involves a large number of experienced laboratories throughout the EU will significantly improve the accident and emergency response capabilities in case of a large-scale radiological emergency. A well organised cooperated action involving EU laboratories will offer the only chance for a fast and trustworthy dose assessment urgently needed in an emergency situation. In this regard the European Commission supports the establishment of an European network in Biological Dosimetry. The goal of RENEB (European Network in Biological Dosimetry) is to establish a sustainable European network in biological dosimetry involving 23 organisations from 16 countries identified by the TENE survey that will guarantee highest efficiency in processing and scoring of biological samples for fast, reliable results implemented in the EU emergency management. This goal will be achieved through five tasks: 1) To create an operational basis of the network, based on coordination of the existing reliable and proven methods in biological dosimetry. 2) To expand and improve the network implementing appropriate new, molecular biology methods and integrating new partners. 3) To assure high quality standards by education and training activities of members and interested non-members. Here, special focus will be placed on quality assurance and management regarding the performed assays and involved laboratories. 4) To develop an operational structure of the network including contacts to national first responders, a well organised transnational infrastructure to facilitate cross-border transport of human biological samples, a long term funding strategy and to prepare an agenda to transform RENEB into a legal organisation. 5) To guarantee dissemination of knowledge by providing access to internal and external communication platforms and databases and close cooperation with national and global emergency preparedness systems and organisations.
1.0 INTRODUCTION

Over the last few years, the risk of a large scale radiological event has markedly increased, not only due to possible accidents in nuclear facilities but also as a result of an enhanced threat of terrorist attacks against key facilities or civil targets in major cities. Events that highlight the need to be prepared for possible radiological accidents or attacks include the Tokaimura event in 1999, the September 11th attacks in 2001, the Madrid train bombings in 2004 and the polonium-210 poisoning of Alexander Litvinenko in 2006. The extent of the damage caused by the Fukushima nuclear power plant disaster in the wake of the earthquake and tsunami in Japan in 2011 is still beyond estimation. Furthermore, according to the judgment of national and international security authorities, it is a question of when, not if, terrorist groups will have the know-how to use radiological devices [“dirty bomb” or Radiation Exposure Device (RED)] to attack the public.

It can be expected that the malevolent attacks will occur without any advance warning and will target as many people as possible in order to cause the maximum damage. Following such a scenario, the triage of patients according to their degree of injury and exposure will be one of the initial steps within the emergency management. The situation during large scale accidents may differ; as often advance warning allows for precise dose surveillance within the disaster area and close monitoring of the distribution of released radionuclides. However, in such a case, the identification and assurance of the huge number of ‘worried well’ individuals, i.e. persons who are extremely distressed but have not actually received radiation doses likely to cause acute health effects, will be most important in order to prevent the healthcare infrastructure being overwhelmed and to avoid socio-economic harm.

In both contexts, biological dosimetry is an essential tool to estimate an absorbed dose without being influenced by temporal or individual variations in blood counts or confounding factors such as chemical agents or psychogenic reactions. Biological dosimetry helps to identify those individuals, needing extensive medical care due to severe irradiation from other people, perhaps with other injuries, but having not received such doses of ionising radiation\(^1\).

In such a large-scale radiological accident or terrorist incident the number of people that may need to be screened thus could easily exceed the capacity of a single or even a number of laboratories. As a consequence biodosimetry networking has been recognised as a sensible and important emergency response strategy in several regions of the world\(^2\). A network of six laboratories has been set up, under the patronage of IAEA, covering Latin American region. A global approach was started by WHO with BioDoseNet\(^3\). At national level networks have been established in Japan\(^4\) and Canada\(^5\) while in Europe a tri-partite memorandum-of-understanding for mutual assistance has existed since 2004 between France, Germany and the United Kingdom. However, this European agreement affects only serious radiological events in these three countries and only one laboratory per country is involved, so the total capacity is also extremely limited. A part of the response is RENEB, an Operational European Network of Biodosimetry we intend to realize in the next 4 years.

2.0 RENEB ORGANISATION

In 2009, all existing European laboratories with considerable experience in biological dosimetry were identified and listed with the help of the TENEB survey\(^6\). Since then, many of these laboratories have expressed their interest in a long term commitment to contributing to a European biodosimetry network. Now, 23 of these institutions from 16 EU countries have formed the RENEB consortium to realise this network. All partners are listed in table 1.
Table 1: RENEB partners

<table>
<thead>
<tr>
<th>Participant</th>
<th>Organisation name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>BfS</td>
<td>Bundesamt für Strahlenschutz</td>
<td>Germany</td>
</tr>
<tr>
<td>BIR/UULM</td>
<td>Bundeswehr Institut für Radiobiologie in Verbindung mit der Universität Ulm</td>
<td>Germany</td>
</tr>
<tr>
<td>CEA</td>
<td>Commissariat à l’Énergie Atomique</td>
<td>France</td>
</tr>
<tr>
<td>ENEA</td>
<td>Agenzia Nazionale per le Nuove Tecnologie, L’Energia e lo Sviluppo Economico Sostenibile</td>
<td>Italy</td>
</tr>
<tr>
<td>HMGU</td>
<td>Helmholtz Centre Munich</td>
<td>Germany</td>
</tr>
<tr>
<td>HPA</td>
<td>Health Protection Agency</td>
<td>UK</td>
</tr>
<tr>
<td>ICHTJ</td>
<td>Institut Chemii i Techniki Jadrowej</td>
<td>Poland</td>
</tr>
<tr>
<td>INSP</td>
<td>Institutul National de Sanatate Publica</td>
<td>Romania</td>
</tr>
<tr>
<td>IRSN</td>
<td>Institut de Radioprotection et de Sûreté Nucléaire</td>
<td>France</td>
</tr>
<tr>
<td>ISS</td>
<td>Instituto Superiore di Sanità</td>
<td>Italy</td>
</tr>
<tr>
<td>IST/ITN</td>
<td>Instituto Tecnológico e Nuclear, Instituto Superior Técnico, Universidade Técnica de Lisboa (IST/ITN, Portugal)</td>
<td>Portugal</td>
</tr>
<tr>
<td>LAFE</td>
<td>Fundacion para la Investigation del Hospital Universitario la Fe de la Comunidad Valenciana</td>
<td>Spain</td>
</tr>
<tr>
<td>LUMC</td>
<td>Leiden University Medical Center</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>NCRRP</td>
<td>National Center for Radiobiology and Radiation Protection</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>NCSR D</td>
<td>National Centre for Scientific Research “Demokritos”</td>
<td>Greece</td>
</tr>
<tr>
<td>NRIRR</td>
<td>National Research Institute for Radiobiology &amp; Radiohygiene</td>
<td>Hungary</td>
</tr>
<tr>
<td>NRPA</td>
<td>Norwegian Radiation Protection Authority</td>
<td>Norway</td>
</tr>
<tr>
<td>STUK</td>
<td>Radiation and Nuclear Safety Authority</td>
<td>Finland</td>
</tr>
<tr>
<td>SU</td>
<td>Stockholm University</td>
<td>Sweden</td>
</tr>
<tr>
<td>UAB</td>
<td>Universitat Autonoma de Barcelona</td>
<td>Spain</td>
</tr>
<tr>
<td>UGent</td>
<td>Universiteit Gent</td>
<td>Belgium</td>
</tr>
<tr>
<td>UNITUS</td>
<td>University of Tuscia</td>
<td>Italy</td>
</tr>
<tr>
<td>SERMAS</td>
<td>Servicio Madrileño de Salud -.Hospital General Universitario Gregorio Marañón -</td>
<td>Spain</td>
</tr>
</tbody>
</table>

3.0 CONTENTS OF RENEB

The structure of RENEB is divided in 6 WorkPackages (WP) whose the first 5 are described hereafter, the last one being the management of the whole project.
3.1 Operational Basis (WP1)

A variety of methods are available that can be used as biodosimeters or as markers of exposure\(^7\). Currently, the best methods of biological dosimetry are based on the analysis of chromosomal damage (dicentric chromosomes, micronuclei and translocations) in peripheral blood lymphocytes\(^8,9\) and electron paramagnetic resonance in bone and tooth enamel\(^10\). These methods have been validated in a number of small-scale radiation accidents and have been shown to be reliable tools to detect an absorbed dose of radiation with sufficient precision. Indeed, the dicentric assay is regarded as the “gold standard” of biodosimetry\(^11\). A number of new biodosimetric methods have recently been introduced, such as premature chromosome condensation (PCC), fluorescence in situ hybridisation (FISH) and γ-H2AX foci\(^7, 9, 12\). In addition, the EPR/OSL method on personal objects (portable electronic devices, chip cards), although strictly speaking not a biodosimetric method, has been shown to have the potential to be an excellent supplementary dosimetry tool\(^9\). As has been shown in a recent survey\(^6\), one or more of these methods are established in many European laboratories, but what is lacking is formal networking, which would facilitate the standardisation of the assays. RENEB will provide a framework for regular intercomparison studies and accident exercises that will guarantee rapid response and reliable dose estimates from all partner laboratories. In this regard, RENEB will run a “ready to use” operational basis which starts with 6 established biodosimetric tools, specified in table 2.

Table 2: Operational basis of biodosimetric assays in RENEB

<table>
<thead>
<tr>
<th>Biodosimetric Assay</th>
<th>Acronym</th>
<th>Illustration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dicentric assay</td>
<td>Dic assay</td>
<td><img src="image1.png" alt="Dic assay image" /></td>
</tr>
<tr>
<td>Fluorescence in situ hybridisation</td>
<td>FISH assay</td>
<td><img src="image2.png" alt="FISH assay image" /></td>
</tr>
<tr>
<td>Micronucleus assay</td>
<td>MN assay</td>
<td><img src="image3.png" alt="MN assay image" /></td>
</tr>
<tr>
<td>Premature chromosome condensation</td>
<td>PCC assay</td>
<td><img src="image4.png" alt="PCC assay image" /></td>
</tr>
<tr>
<td>γ-H2AX assay</td>
<td>γ-H2AX assay</td>
<td><img src="image5.png" alt="γ-H2AX assay image" /></td>
</tr>
</tbody>
</table>
All these techniques will be compared, standardized and harmonized in the participating laboratories to guarantee the highest possible reliability and accuracy.

3.2 Basis for Extending the Network (WP2)

The established network is not designed to be a static or closed consortium; the sustainability will rather depend on openness and the ability to react in a flexible way towards new situations. This implies the awareness of new technological developments as well as dealing with the loss and gain of network members. Thus, it is a major goal of the RENEB consortium to actively identify promising techniques and potential new partners.

In this regard a roadmap of how to identify, validate, verify and integrate new technologies into the existing network will be developed. In parallel, a multi-stage procedure will be adopted to recognize and integrate new partners into the established network. This will involve identification, recruitment and training of candidate partners and the development of the formal criteria for their membership. The assessment of prospective laboratory capacities among consortium members and potential new network partners will further support the systematic build-up of the network. This concerns also new partners working with established and validated methods already integrated in the network. In this case, the adoption of the network standard has to be ensured. Candidate partners bringing new but already validated techniques will be required to provide access for the existing partners.

3.3 Quality, Education and Training (WP3)

In the event of an accident involving a large number of potentially irradiated people, the prioritization of resources by effective triage procedures becomes the key issue. The true value of biological dosimetry lies in the speed with which this information can be made available to the physicians, and the response time of the network depends chiefly on the efficiency of all labs involved in the response, not only individually but also in coordination. The best operational conditions result directly from the preparedness of the network before the event. Such provisions include harmonisation of procedures among the individual laboratories, retention of qualified staff, knowledge of the laboratory capacity in crisis situations and common training through implementation of periodic exercises. In this regard, quality management has a large influence on both, the operational basis of the network which includes proven and applied techniques and further development of the network which deals with new methodologies and new partners. The quality management structure thus handles operations that are directed towards project members, but also towards non-members. Within a long-term education & training programme technical exercises according to the recommendations of ISO standards will be performed on a regular basis. This training will be based upon the recommendations of the appropriate international (ISO) standards and will establish periodic intra- and intercomparisons (for the qualification of the network). The programme will also include theoretical calculations and experimental design as well. This will provide the opportunity for members to enlarge their spectrum of methodologies by establishing validated assays on an operational basis in their laboratories. There will be efforts to connect this long-term training program to already existing European and global training platforms such as those supported by ENEN, ENETRAP, ENSTTI and IAEA.
A Quality Assurance & Quality Management (QA&QM) programme is also included as an essential part of Education & Training for RENEB. It is necessary for the network that the results will be homogeneous across all associated laboratories, irrespective of the particular organisation of the laboratory. The ISO standards 19238:2004 and 21243:2008\(^{13, 14}\) provide standardised guidance for all partners in order to perform the dicentric assay in a reproducible and accurate manner\(^{15}\). The approaches described in these standards include pre-planning, networking, reagent stockpiling, simplified sample processing, automation, medical management, radiation protection management, record keeping and medical/legal requirements, qualification of staff and inter-comparisons. For the EPR technique and micronucleus assay respectively, ISO standards are currently being prepared and should be published within the next few years. For the assays used in RENEB for which standards are not yet available, many parts of the existing standards can be easily adapted.

### 3.4 Long term Sustainability of the Network (WP4)

Besides the maintenance of established methods, the openness to new techniques and partners, safeguarding of high quality standards and education and training provisions, RENEB will need a formal legal status to act as an official unit. This will be based on the development of an appropriate agenda which is valid in all countries of the partner organisations and respects the intrinsic ethical standards. In addition to the legal framework financial support is needed to keep the network alive. In this context, funding options beyond the emergency preparedness system will offer an independent source to allow active operations. A long-term funding strategy will be provided by connecting RENEB capabilities to the European research area and by establishing links to public health organisations. The network with its capability to analyse large numbers of samples can contribute to the wider field of radiation protection, for example to investigate large and complex topics like radiosensitivity, radionuclide incorporation, inhomogeneous exposure or discovery and validation of new bioindicators and methods. It can thus be useful for a large number of benefactors in different areas of the general community. Here, it is envisaged that the network will interact with research platforms such as MELODI (Multidisciplinary European Low Dose Initiative). The funding strategy should increase stakeholder awareness, that a strong and
sustainable biodosimetry network provides very valuable information about the impact of new radiation
technologies in medicine and industry on public health and may support the development of
individualised cancer therapies as well.

Moreover, an efficient and smooth flow of action in the case of an emergency event will be extremely
valuable during an emergency situation. In this regard, communication and logistical infrastructures will
be improved.

3.5 Dissemination of RENEB - integration in international emergency preparedness
systems (WP5)

It is crucial for RENEB to maintain strong links and cooperation with European and international
organisations, European Union agencies and national bodies involved in emergency preparedness and
response. A promising basis is the already existing involvement of several RENEB partners in
international activities like the WHO BioDoseNet\(^3\) and REMPAN\(^{17}\) and the IAEA RANET\(^{18}\), as well
as the contact with other relevant national and international organizations including European Union
agencies and national bodies involved in decision-making for arrangements in emergency preparedness
and response. Contacts to the national bodies responsible for biodosimetry arrangements will be
facilitated by national representatives from the RENEB consortium countries. Furthermore, information
about the development of the network will be available through presentations during the relevant
radiation research and emergency preparedness meetings and state-of-the-art web pages. Here, RENEB
can communicate with internal partners, as well as disseminate the activities of the network to the public.
There will also be a link to radiation protection institutions, national competent authorities in emergency
preparedness and response, UN organisations like the IAEA and WHO and other international
institutions, non-governmental bodies such as EURADOS, and academic institutions.

As shown in figure 1, all tasks are linked and will complete each other. Close interaction will especially
be established between the network tasks “Operational Basis”, “Development” and “Quality Assurance”.
The tasks “Sustainability” and “Dissemination” will be based on these functions.

4.0 CONCLUSION (TEMPORARY)

In January 2012 the first RENEB meeting was held in Berlin to put the European biodosimetry network
into action. A total of 53 participants attended the meeting, most of them members of the 23 partner
organisations but also experts from IAEA, WHO and EC organisations. During this meeting the practical
application of the project along and after the next 4 years was discussed.

Of course, it is expected to provide fast and reliable biological dose estimation in case of an emergency
for first medical purpose and later socio-economic purpose.

But more could be expected: (i) The actions designed inside RENEB for training and establishing
QA&QM programs in all RENEB partners are a good way for building a high level research network; (ii)
Some possibility of integration of new bio-indicators of exposure, more sensitive and/or more specific,
could exist in the continuation of RENEB; (iii) Therefore, to solve the problem of network sustainment
after the EU-project phase, there is an great interest to integrate the RENEB project in some existing
European platforms (e.g MELODI), regarding these new bio-indicators of exposure which could be
applied at low dose, chronic exposure situations.

5.0 ACKNOWLEDGEMENTS

This work is supported by the EU within the 7th Framework Programme, grant agreement no. 295513.
6.0 REFERENCES


